Physician profile
Laura F Mitchell
NPI 1225269905
$2,777.75
in general payments reported to CMS, 2019-2025
19 companies · $785 in 2025
The $785 reported for 2025 was more than what a typical Oncology (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $263).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $175 · 2023: $1,036 · 2024: $781 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,603.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $352.41 | 2023-2025 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $325.71 | 2024-2025 | Opdivo |
| Janssen Biotech, INC. | $272.49 | 2023-2025 | Carvykti, Tecvayli, Darzalex |
| Gilead Sciences, INC. | $244.70 | 2024-2025 | Trodelvy |
| Amgen INC. | $244.70 | 2023-2024 | Lumakras |
| Bayer Healthcare Pharmaceuticals INC. | $224.13 | 2022-2025 | |
| Novo Nordisk INC | $144.35 | 2024-2025 | Novoseven, Wegovy |
| Rigel Pharmaceuticals, INC. | $124.74 | 2023 | Tavalisse, Rezlidhia |
| Genmab U.S., INC. | $116.55 | 2024 | Epkinly |
| Pfizer INC. | $104.55 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.71 | 2025 | Fruzaqla |
| Abbvie INC. | $93.16 | 2024 | |
| Puma Biotechnology, INC. | $91.09 | 2023 | Nerlynx |
| Jazz Pharmaceuticals INC. | $90.60 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $89.92 | 2023 | Tagrisso |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $72.18 | 2023 | Lunsumio |
| Sobi, INC | $50.00 | 2022 | |
| Incyte Corporation | $19.35 | 2023 | Jakafi |
| Regeneron Healthcare Solutions, INC. | $16.41 | 2025 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.